Antimicrobial activity of closthioamide compared with established drugs against laboratory strains
| Strain . | . | Gram+/Gram− . | MIC (mg/L)a . | ||
|---|---|---|---|---|---|
| . | closthioamide . | closthioamide + PMBNb . | ciprofloxacin . | ||
| MRSA | LT-1334 | Gram+ | 0.14 | NA | ND |
| MRSA | USA300 | Gram+ | 0.04 | NA | >5 |
| S. aureus | SG 511 | Gram+ | 0.07 | NA | ND |
| S. aureus | RN4220 | Gram+ | 0.04 | NA | 0.2 |
| S. simulans | 22 | Gram+ | 0.05 | NA | 0.03 |
| Enterococcus faecium | I-11054 | Gram+ | 0.04 | NA | >25 |
| VRE | BM 4147 | Gram+ | 0.4 | NA | 1.6 |
| B. subtilis | 168 | Gram+ | 0.23 | NA | ND |
| E. coli | BW25113c | Gram− | 3.75 | 0.625 | ND |
| E. coli | JW0452 (ΔacrA)d | Gram− | 0.31 | 0.035 | ND |
| E. coli | O-19592 | Gram− | 2.5 | ND | 12.5 |
| E. coli | I-11054 | Gram− | 3.5 | ND | ND |
| Strain . | . | Gram+/Gram− . | MIC (mg/L)a . | ||
|---|---|---|---|---|---|
| . | closthioamide . | closthioamide + PMBNb . | ciprofloxacin . | ||
| MRSA | LT-1334 | Gram+ | 0.14 | NA | ND |
| MRSA | USA300 | Gram+ | 0.04 | NA | >5 |
| S. aureus | SG 511 | Gram+ | 0.07 | NA | ND |
| S. aureus | RN4220 | Gram+ | 0.04 | NA | 0.2 |
| S. simulans | 22 | Gram+ | 0.05 | NA | 0.03 |
| Enterococcus faecium | I-11054 | Gram+ | 0.04 | NA | >25 |
| VRE | BM 4147 | Gram+ | 0.4 | NA | 1.6 |
| B. subtilis | 168 | Gram+ | 0.23 | NA | ND |
| E. coli | BW25113c | Gram− | 3.75 | 0.625 | ND |
| E. coli | JW0452 (ΔacrA)d | Gram− | 0.31 | 0.035 | ND |
| E. coli | O-19592 | Gram− | 2.5 | ND | 12.5 |
| E. coli | I-11054 | Gram− | 3.5 | ND | ND |
NA, not applicable; ND, not determined.
aAverage of two or more experiments made in duplicate.
bPMBN at 50 μg/mL; induces membrane permeabilization.
cParent strain of E. coli JW0452.
dDrug efflux pump-deficient mutant.
Antimicrobial activity of closthioamide compared with established drugs against laboratory strains
| Strain . | . | Gram+/Gram− . | MIC (mg/L)a . | ||
|---|---|---|---|---|---|
| . | closthioamide . | closthioamide + PMBNb . | ciprofloxacin . | ||
| MRSA | LT-1334 | Gram+ | 0.14 | NA | ND |
| MRSA | USA300 | Gram+ | 0.04 | NA | >5 |
| S. aureus | SG 511 | Gram+ | 0.07 | NA | ND |
| S. aureus | RN4220 | Gram+ | 0.04 | NA | 0.2 |
| S. simulans | 22 | Gram+ | 0.05 | NA | 0.03 |
| Enterococcus faecium | I-11054 | Gram+ | 0.04 | NA | >25 |
| VRE | BM 4147 | Gram+ | 0.4 | NA | 1.6 |
| B. subtilis | 168 | Gram+ | 0.23 | NA | ND |
| E. coli | BW25113c | Gram− | 3.75 | 0.625 | ND |
| E. coli | JW0452 (ΔacrA)d | Gram− | 0.31 | 0.035 | ND |
| E. coli | O-19592 | Gram− | 2.5 | ND | 12.5 |
| E. coli | I-11054 | Gram− | 3.5 | ND | ND |
| Strain . | . | Gram+/Gram− . | MIC (mg/L)a . | ||
|---|---|---|---|---|---|
| . | closthioamide . | closthioamide + PMBNb . | ciprofloxacin . | ||
| MRSA | LT-1334 | Gram+ | 0.14 | NA | ND |
| MRSA | USA300 | Gram+ | 0.04 | NA | >5 |
| S. aureus | SG 511 | Gram+ | 0.07 | NA | ND |
| S. aureus | RN4220 | Gram+ | 0.04 | NA | 0.2 |
| S. simulans | 22 | Gram+ | 0.05 | NA | 0.03 |
| Enterococcus faecium | I-11054 | Gram+ | 0.04 | NA | >25 |
| VRE | BM 4147 | Gram+ | 0.4 | NA | 1.6 |
| B. subtilis | 168 | Gram+ | 0.23 | NA | ND |
| E. coli | BW25113c | Gram− | 3.75 | 0.625 | ND |
| E. coli | JW0452 (ΔacrA)d | Gram− | 0.31 | 0.035 | ND |
| E. coli | O-19592 | Gram− | 2.5 | ND | 12.5 |
| E. coli | I-11054 | Gram− | 3.5 | ND | ND |
NA, not applicable; ND, not determined.
aAverage of two or more experiments made in duplicate.
bPMBN at 50 μg/mL; induces membrane permeabilization.
cParent strain of E. coli JW0452.
dDrug efflux pump-deficient mutant.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
